In our June 13, 2011 article (Med Lett Drugs Ther 2011; 53:46), we said that the FDA has approved Nuedexta for treatment of pseudobulbar affect in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). That is not quite correct. The package insert says that the drug is indicated for the treatment of pseudobulbar affect and then goes on to say, in the next two sentences, that studies to support the effectiveness of Nuedexta were performed in patients with underlying ALS or MS, and that the drug has not been shown to be safe or effective in other types of emotional lability. Also, the second sentence in the Drug Interactions paragraph should have said: "Other drugs that prolong the QT interval, inhibit CYP3A4, or are metabolized by CYP2D6 and prolong the QT interval, should be used with caution, if at all."